Drug-Induced Ocular Toxicity — Glaucoma & Anterior Segment

Overview

Drug-induced toxicity affecting the glaucoma and anterior-segment structures is a distinct category from drug-induced retinal toxicity (hydroxychloroquine, tamoxifen, and the other classic retina-toxicity drugs). These mechanisms spare the photoreceptors and retinal pigment epithelium entirely. Instead they act on angle anatomy, trabecular meshwork outflow resistance, iris and ciliary body musculature, and the corneal endothelium and lens capsule. A drug can raise pressure by crowding the angle, by obstructing the trabecular meshwork's own outflow machinery, by paralyzing the muscle that holds the iris rigid during surgery, or by poisoning the ciliary epithelium that produces aqueous. Four distinct failure points, and all four converge on the same nonspecific presentation: red eye, pain, and blurred vision.

Several of these mechanisms look alike at presentation but call for opposite management. Two separate drug groups both produce acute angle closure through nearly opposite mechanisms, and treating one with the standard regimen for the other can make the patient worse.

Clinical Features

Drug-Induced Angle Closure

Acute angle closure has two mechanistically distinct causes among systemic drugs, and the exam-writer's favorite trick is to describe one and expect the other's treatment.

Ciliochoroidal effusion (non-pupillary-block) angle closure. Topiramate, an anticonvulsant and migraine prophylaxis drug that is chemically a sulfonamide derivative, causes an idiosyncratic ciliochoroidal effusion in a small subset of patients, typically within the first days to weeks of starting the drug or after a dose increase. The effusion rotates the ciliary body anteriorly, pushing the entire iris-lens diaphragm forward. The result is a sudden, often marked myopic shift (patients frequently report their distance vision has gone blurry over a day or two) with bilateral acute angle closure. The pupil is not the problem: there is no pupillary block at all, since the angle is closing because the whole diaphragm has been pushed forward mechanically from behind. Sulfonamide antibiotics (e.g., trimethoprim-sulfamethoxazole) share the sulfa chemical backbone with topiramate and can trigger the identical idiosyncratic mechanism: bilateral acute myopia and angle closure, again without pupillary block, again typically within days of starting the drug.

Pupillary-block angle closure from mydriasis. This is the more familiar mechanism, and it works through the pupil rather than around it. Systemic anticholinergics (scopolamine is the classic example) block iris sphincter tone, producing pupillary mydriasis. In an eye that already has an anatomically narrow angle, that mydriasis is enough to crowd the angle further and precipitate true pupillary-block angle closure. Tricyclic antidepressants (TCAs) carry significant anticholinergic activity and produce the same mydriasis-driven angle-closure risk in predisposed eyes. They also cause a separate, more common anticholinergic effect: cycloplegia (paralysis of accommodation), which shows up as blurred near vision rather than an ocular emergency.

Intraoperative Floppy Iris Syndrome

Tamsulosin, an alpha-1a adrenergic antagonist used for benign prostatic hyperplasia, is the drug most strongly associated with intraoperative floppy iris syndrome (IFIS). Its selectivity for the alpha-1a receptor subtype concentrated in the iris dilator muscle causes atrophy of that muscle over time. During cataract surgery, an IFIS iris billows in the anterior chamber currents, progressively constricts despite pharmacologic dilation, and tends to prolapse toward the phaco incision. All three behaviors raise the risk of intraoperative complications if the surgeon isn't prepared for them. The detail that catches people off guard: because the effect is on the iris dilator muscle itself rather than on circulating drug levels, IFIS risk persists even after tamsulosin has been discontinued, sometimes for years.

Steroid-Induced Glaucoma & Cataract

Chronic corticosteroid exposure, systemic or topical, raises IOP in susceptible "steroid responder" patients by a specific mechanism: increased resistance to aqueous outflow at the trabecular meshwork, driven by glycosaminoglycan accumulation and altered cytoskeletal proteins within trabecular meshwork cells. The wrong mechanism is a common distractor: steroid glaucoma is not caused by decreased episcleral venous pressure, enhanced uveoscleral outflow, or reduced aqueous production. It is purely an outflow problem at the trabecular meshwork.

Long-term steroid use is also classically linked to posterior subcapsular cataract (PSC). Steroids disrupt lens epithelial cell metabolism and ion transport, and the resulting opacification accumulates just under the posterior capsule. That location sits directly in the visual axis near the nodal point, so PSC produces symptoms out of proportion to its size: disproportionate glare (especially with pupillary constriction, as in bright light or reading) and disabling near vision loss even when the cataract looks modest on slit lamp exam.

Other Anterior Segment Drug Reactions

Isotretinoin, used for severe acne, causes meibomian gland atrophy and reduced tear film quality, commonly presenting as blepharoconjunctivitis and dry eye during treatment. A second, unrelated effect involves the central nervous system: isotretinoin has been linked to idiopathic intracranial hypertension (pseudotumor cerebri) causing papilledema, and that risk rises further when isotretinoin is combined with tetracycline antibiotics, which is why the combination is generally avoided.

Chlorpromazine, a phenothiazine antipsychotic, deposits stellate, granular pigment in the corneal endothelium and anterior lens capsule with chronic high-dose use. The finding is distinctive on exam but usually causes little or no visual impairment.

Bisphosphonates (pamidronate, zoledronic acid) can trigger scleritis or anterior uveitis, thought to relate to cytokine release from the infusion, and this typically appears within days of a dose.

Rifabutin-associated anterior uveitis, seen in HIV and mycobacterial treatment regimens, has a specific and testable drug-interaction trigger: concurrent clarithromycin inhibits cytochrome P450 metabolism of rifabutin, raising serum rifabutin levels and significantly increasing uveitis risk.

Cidofovir, given intravenously for CMV (cytomegalovirus) retinitis, is directly toxic to the nonpigmented epithelium of the ciliary body. That toxicity suppresses aqueous production and can cause severe, sometimes irreversible ocular hypotony, often together with anterior uveitis. The contrast with steroid-induced glaucoma above is instructive: one drug class shuts aqueous production down hard enough to cause hypotony, the other blocks outflow hard enough to cause glaucoma.

Systemic beta-blockers decrease lacrimal gland secretion and tear film stability, commonly causing or worsening dry eye. The same drug class lowers IOP when given as a topical glaucoma drop, but taken systemically for hypertension or cardiac disease, its dominant ocular effect is on the tear film rather than intraocular pressure.

Management

For IFIS, management is about anticipation rather than in-the-moment rescue. The surgeon needs to know about any tamsulosin history, including past discontinued use, before starting, so pupil-expansion devices (iris hooks, a Malyugin ring) and a modified phaco technique are ready from the start rather than reached for mid-complication.

For patients on chronic corticosteroids, especially known steroid responders, routine IOP monitoring is the core preventive measure, since steroid-induced pressure elevation is otherwise silent until optic nerve damage has already begun.

The angle-closure distinction matters most for management. True pupillary-block angle closure (anticholinergic/TCA-mediated) responds to the standard regimen: miotics to pull the peripheral iris away from the angle, then definitive treatment with laser peripheral iridotomy once the acute attack is controlled. Ciliochoroidal-effusion angle closure from topiramate or a sulfonamide antibiotic is different. The pupil was never the problem, so the mainstay is stopping the culprit drug and treating the underlying effusion (cycloplegia, aqueous suppressants, sometimes short-term corticosteroids), not an iridotomy.

High-Yield Pearls

The sharpest distinction in this cluster is angle-closure mechanism: topiramate and sulfonamides push the diaphragm forward from behind (ciliochoroidal effusion, no pupillary block, stop the drug), while anticholinergics and TCAs dilate the pupil into an already-narrow angle (true pupillary block, miotics and iridotomy). Every other entity here, IFIS, steroid glaucoma with PSC cataract, and the individual anterior-segment reactions, is best remembered as a one-drug-one-mechanism pairing rather than grouped by presenting symptom, since red eye and blurred vision are the final common pathway for nearly all of them.

Related Topics

Continue exploring Systemic Disease & the Eye: